DK1529116T3 - Fremgangsmåde til forudsigelse af respons på behandling med rivastigmin baseret på ApoE-genotypen hos demenspatienter - Google Patents
Fremgangsmåde til forudsigelse af respons på behandling med rivastigmin baseret på ApoE-genotypen hos demenspatienterInfo
- Publication number
- DK1529116T3 DK1529116T3 DK03747881T DK03747881T DK1529116T3 DK 1529116 T3 DK1529116 T3 DK 1529116T3 DK 03747881 T DK03747881 T DK 03747881T DK 03747881 T DK03747881 T DK 03747881T DK 1529116 T3 DK1529116 T3 DK 1529116T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment based
- dementia patients
- predicting response
- apoe genotype
- rivastigmine treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40169402P | 2002-08-07 | 2002-08-07 | |
| PCT/EP2003/008719 WO2004015140A1 (en) | 2002-08-07 | 2003-08-06 | Methods for the treatment of dementia based on apo e genotype |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1529116T3 true DK1529116T3 (da) | 2009-11-09 |
Family
ID=31715721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03747881T DK1529116T3 (da) | 2002-08-07 | 2003-08-06 | Fremgangsmåde til forudsigelse af respons på behandling med rivastigmin baseret på ApoE-genotypen hos demenspatienter |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20060160079A1 (da) |
| EP (1) | EP1529116B1 (da) |
| JP (1) | JP2005534710A (da) |
| CN (1) | CN1681941A (da) |
| AT (1) | ATE435302T1 (da) |
| AU (1) | AU2003266967B2 (da) |
| BR (1) | BR0313588A (da) |
| CA (1) | CA2494585A1 (da) |
| DE (1) | DE60328198D1 (da) |
| DK (1) | DK1529116T3 (da) |
| ES (1) | ES2327914T3 (da) |
| IL (1) | IL166466A0 (da) |
| PT (1) | PT1529116E (da) |
| WO (1) | WO2004015140A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| CA2571856A1 (en) * | 2004-07-20 | 2006-02-09 | Wyeth | Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer's disease |
| EP1859056A2 (en) * | 2005-01-31 | 2007-11-28 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
| US7740593B2 (en) | 2005-12-09 | 2010-06-22 | Senorx, Inc | Guide block for biopsy or surgical devices |
| EP2650379B1 (en) | 2007-07-31 | 2015-09-16 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| WO2010003114A1 (en) | 2008-07-03 | 2010-01-07 | Neuera Pharmaceuticals, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
| CA3057289A1 (en) | 2017-03-21 | 2018-09-27 | The Jackson Laboratory | A genetically modified mouse expressing human apoe4 and mouse trem2 p.r47h and methods of use thereof |
| HUE053636T2 (hu) * | 2017-05-24 | 2021-07-28 | H Lundbeck As | 5-HT6 receptor antagonista és acetilkolin-észteráz inhibitor kombinációja Alzheimer-kór kezelésében történõ alkalmazásra ApoE4 alléleket hordozó betegek szubpopulációjában |
| US20210195879A1 (en) * | 2018-06-21 | 2021-07-01 | The Jackson Laboratory | Genetically modified mouse models of alzheimer's disease |
| WO2020176846A2 (en) * | 2019-02-28 | 2020-09-03 | The Rockefeller University | Apoe genotyping in cancer prognostics and treatment |
| PL4073025T3 (pl) | 2019-12-13 | 2024-09-16 | Inspirna, Inc. | Sole metali i ich zastosowania |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE625212T1 (de) * | 1992-10-13 | 2000-11-02 | Duke University, Durham | Verfahren zum entdecken von krankheit von alzheimer. |
| CA2111503A1 (en) * | 1993-12-15 | 1995-06-16 | Mcgill University | Apolipoprotein e polymorphism and alzheimer's disease |
| FR2765591B1 (fr) * | 1997-07-01 | 2002-08-09 | Pasteur Institut | Procede de diagnostic de la maladie d'alzheimer |
| CO4980891A1 (es) * | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
| JP2000069963A (ja) * | 1998-08-31 | 2000-03-07 | Igaku Seibutsugaku Kenkyusho:Kk | アポリポプロテインｅ４特異モノクローナル抗体 |
| DE69923200T2 (de) * | 1998-10-01 | 2005-12-22 | Novartis Ag | Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe |
| US7034182B2 (en) * | 2000-06-30 | 2006-04-25 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
-
2003
- 2003-08-06 AT AT03747881T patent/ATE435302T1/de not_active IP Right Cessation
- 2003-08-06 CA CA002494585A patent/CA2494585A1/en not_active Abandoned
- 2003-08-06 US US10/523,047 patent/US20060160079A1/en not_active Abandoned
- 2003-08-06 ES ES03747881T patent/ES2327914T3/es not_active Expired - Lifetime
- 2003-08-06 DE DE60328198T patent/DE60328198D1/de not_active Expired - Lifetime
- 2003-08-06 JP JP2004526899A patent/JP2005534710A/ja active Pending
- 2003-08-06 WO PCT/EP2003/008719 patent/WO2004015140A1/en active Application Filing
- 2003-08-06 EP EP03747881A patent/EP1529116B1/en not_active Expired - Lifetime
- 2003-08-06 BR BR0313588-8A patent/BR0313588A/pt not_active Application Discontinuation
- 2003-08-06 AU AU2003266967A patent/AU2003266967B2/en not_active Ceased
- 2003-08-06 CN CNA038212528A patent/CN1681941A/zh active Pending
- 2003-08-06 DK DK03747881T patent/DK1529116T3/da active
- 2003-08-06 PT PT03747881T patent/PT1529116E/pt unknown
-
2005
- 2005-01-24 IL IL16646605A patent/IL166466A0/xx unknown
-
2007
- 2007-11-16 US US11/941,420 patent/US20080214662A1/en not_active Abandoned
-
2010
- 2010-06-03 US US12/793,436 patent/US20100240744A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE435302T1 (de) | 2009-07-15 |
| AU2003266967A1 (en) | 2004-02-25 |
| EP1529116B1 (en) | 2009-07-01 |
| US20060160079A1 (en) | 2006-07-20 |
| BR0313588A (pt) | 2005-07-12 |
| ES2327914T3 (es) | 2009-11-05 |
| CN1681941A (zh) | 2005-10-12 |
| PT1529116E (pt) | 2009-09-10 |
| AU2003266967B2 (en) | 2006-11-16 |
| EP1529116A1 (en) | 2005-05-11 |
| DE60328198D1 (de) | 2009-08-13 |
| CA2494585A1 (en) | 2004-02-19 |
| IL166466A0 (en) | 2006-01-15 |
| US20100240744A1 (en) | 2010-09-23 |
| US20080214662A1 (en) | 2008-09-04 |
| JP2005534710A (ja) | 2005-11-17 |
| WO2004015140A1 (en) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL166466A0 (en) | Methods for the treatment of dementia based on apoe genotype | |
| NL301145I2 (nl) | Tirbanibulin | |
| TW200636075A (en) | Detection of nucleic acid variation by cleavage-amplification method | |
| DK1838355T3 (da) | Forbedrede quenching-fremgangsmåder til erytrocyt-inaktiveringsfremgangsmåde | |
| DK1721992T3 (da) | Fremgangsmåder og nukleinsyrer til analyser af cellulære proliferative sygdomme | |
| WO2005077007A3 (en) | Methods of diagnosing and treating pre-eclampsia or eclampsia | |
| IL210065A0 (en) | Improved method and system for detecting and/or predicting biological anomalies, such as cerebral disorders | |
| DE602005005730D1 (de) | Steuerverfahren für Informationbereitstellung, Informationwiedergabesystem und Informationbereitstellungsapparat | |
| WO2006002262A3 (en) | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder | |
| ATE408032T1 (de) | Esr1 und gebärmutterhalskrebs | |
| ATE529799T1 (de) | System und verfahren zur schnellen eingabe von daten | |
| DE602005014134D1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
| ATE469908T1 (de) | Verfahren zur herstellung von pimecrolimus | |
| ATE428417T1 (de) | Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren | |
| DK1718967T3 (da) | Metoder til at detektere Lp-PLA2 aktivitet | |
| ATE549416T1 (de) | Verfahren und zusammensetzungen zum nachweis von autoimmunkrankheiten | |
| DK1730315T3 (da) | Polymorphismer i NOD2/Card15 gen | |
| WO2006036943A3 (en) | Determination of molecular age by detection of ink4a/arf expression | |
| DE602005021889D1 (en) | Substituierte thienopyrrolcarbonsäureamide, pyrrolothiazolcarbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon | |
| DE602006012456D1 (de) | Kühlgerät, steuerverfahren für das kühlgerät und verfahren zur bestimmung von anomalien | |
| WO2003070082A3 (en) | Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer | |
| ATE490959T1 (de) | Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors | |
| DE602005016697D1 (de) | Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen | |
| ATE445592T1 (de) | Derivate von heteroarylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung als faah-enzyminhibitoren | |
| ATE515576T1 (de) | Protein c polymorphismen |